| 注册
首页|期刊导航|疑难病杂志|阿德福韦酯与恩替卡韦治疗低病毒载量代偿期乙肝肝硬化疗效比较

阿德福韦酯与恩替卡韦治疗低病毒载量代偿期乙肝肝硬化疗效比较

毛创杰 王丽 胡蓉 曾义岚 张琼 康信通

疑难病杂志Issue(10):1053-1055,3.
疑难病杂志Issue(10):1053-1055,3.DOI:10.3969/j.issn.1671-6450.2015.10.019

阿德福韦酯与恩替卡韦治疗低病毒载量代偿期乙肝肝硬化疗效比较

Comparison of adefovir and entecavir in treatment with low viral load hepatitis B virus related compensated cirrhosis

毛创杰 1王丽 1胡蓉 1曾义岚 1张琼 1康信通1

作者信息

  • 1. 610000 成都市公共卫生临床医疗中心
  • 折叠

摘要

Abstract

Objectives To compare the curative effect of adefovir dipivoxil ( ADV) and entecavir ( ETV) in the treatment of low viral load decompensated liver cirrhosis .Methods From 2011 Jan to 2012 June, 96 cases of low viral load decompensated liver cirrhosis caused by hepatitis B virus ( HBV-DNA <2.0 ×104 copies/ml) were enrolled, according to random number table, they were divided into two groups, 48 cases received adefovir dipivoxil (ADV group), 48 patients re-ceived ticarcillin anti-viral therapy ( ETV group ) , liver function [ alanine amino transferase ( ALT) , total bilirubin ( TB) , al-bumin ( ALB) ] , renal function , alpha fetal protein , hepatitis B markers , serum HBV-DNA, prothrombin time ( PT) , liver B type ultrasound or CT examination were tested in all patients each 1-3 months.All patients were followed up for 12 months to compare the efficacy and adverse reactions and mortality rate .Results After 12 months, serum HBV-DNA negative conver-sion rate in ADV group and ETV group were 100%, the difference was not statistically significant ( P >0.05);treated for 12 months, ADV group’ s HBeAg serum virological breakthrough rate was 16.7% and 2.1%, ETV group were 14.6% and 4.2%, the difference was not statistically significant ( P >0.05); treated for 12 months, 2 groups’ ALT, TB, Alb, PT were significantly improved ( P <0.05), no statistical significance were found between the two groups ( P >0.05).The se-rum creatinine ( SCr) and lactic acid ( LA) more than the normal value of the upper limit were not found in both of the two groups.ADV group died of 1 case (2.1%), and there was no mortality in ETV group.Conclusion Adefovir dipivoxil or en entecavir treatment for low viral load compensated hepatitis B cirrhosis can significantly inhibited HBV -DNA replication, im-prove liver function indicators , reduce incidence of decompensated , its worthy of clinical application .

关键词

阿德福韦酯/恩替卡韦/低病毒载量/代偿期乙肝肝硬化/疗效

Key words

Adefovir dipivoxil/Entecavir/Low viral load/Decompensated hepatitis B cirrhosis/Curative effect

引用本文复制引用

毛创杰,王丽,胡蓉,曾义岚,张琼,康信通..阿德福韦酯与恩替卡韦治疗低病毒载量代偿期乙肝肝硬化疗效比较[J].疑难病杂志,2015,(10):1053-1055,3.

疑难病杂志

OACSTPCD

1671-6450

访问量0
|
下载量0
段落导航相关论文